Correlation of in vitro bromodeoxyuridine labeling index and DNA aneuploidy with survival or recurrence in brain-tumor patients

Authors:
  • TOTetsuji Orita
    Tetsuji Orita
  • KKKoji Kajiwara
    Koji Kajiwara
  • NINorio Ikeda
    Norio Ikeda
  • NONoboru Ohshita
    Noboru Ohshita
  • HNHisato Nakayama
    Hisato Nakayama
  • YFYasuhiro Furutani
    Yasuhiro Furutani
  • YIYukihide Ikeyama
    Yukihide Ikeyama
  • TATatsuo Akimura
    Tatsuo Akimura
  • TKToshifumi Kamiryo
    Toshifumi Kamiryo
  • HIHaruhide Ito
    Haruhide Ito

Abstract
✓ There are no previous reports correlating the in vitro bromodeoxyuridine (BUdR) labeling index (LI) with the clinical outcome in patients with brain tumors. The reliability of the LI as a predictor of patient survival or recurrence was examined in this study of 66 human brain tumors (19 gliomas, 18 meningiomas, and 29 others). Anti-BUdR staining was performed on surgically extirpated tumor tissue that had been treated with BUdR as previously described. Correlation of the BUdR LI with patient survival or tumor recurrence rate was carried out by the method of Kaplan and Meier. Deoxyribonucleic acid (DNA) aneuploidy was estimated in 52 cases. The results of this study indicate that BUdR LI values correlated well with the clinical course of patients with brain tumor. In comparison with patients with higher LI's, there was both a significantly higher survival rate for tumors other than meningiomas and a higher recurrence-free rate for meningiomas in patients with LI's of less than 4% and 1%, respectively. Al...